National Drug & Alcohol Research Centre Blog

DECEMBER 4, 2023

Kendal Chidwick NDARC’s Kendal Chidwick discusses the findings from a recently published study that examined how patterns of opioid agonist treatment medicines have changed over the past decade. Other changes around this time aimed at improving treatment accessibility included increased use of take-home doses and telehealth appointments.

Treatment 133

Treatment Community Pharmacies Pharmacy International 133

FDA Law Blog: Drug Discovery

MARCH 19, 2023

s Mark Tobolowsky co-authored the peer-reviewed article “ Microdystrophin Expression as a Surrogate Endpoint for Duchenne Muscular Dystrophy Clinical Trials ” in the recently published edition of Human Gene Therapy. Hyman, Phelps & McNamara, P.C.’s

Therapies 98

Therapies Clinical Trials Treatment Trials 98

Drug Target Review

DECEMBER 23, 2024

While these therapies hold great promise for improving cancer treatment outcomes, their development presents significant challenges, especially in achieving the optimal balance between efficacy and safety. Properly managing these toxicities is crucial to enhancing the safety and therapeutic effectiveness of ADC treatments.

Research 52

Research Treatment Therapies Drug Development 52

Drug Target Review

AUGUST 30, 2023

There is significant unmet medical need for effective treatment of neurological disorders, including pain disorders, which have a prevalence of 27.5 9,11 MEA recordings were performed before and acer drug treatment or target knockdown, and the resulting data were analysed using Axion’s Axis Navigator and Neural Metric Tool.

Drugs 105

Drugs RNA Treatment Disease 105

Drug Patent Watch

JANUARY 21, 2025

The rising cost of brand-name medications has left millions of people struggling to afford the treatments they need to manage their conditions. This is a win-win for everyone involved patients get the treatments they need, and healthcare systems can allocate resources more efficiently. Read the full article here: [link]

Biosimilars 95

Biosimilars Government Treatment Pharmaceuticals 95

Drug Target Review

JUNE 8, 2023

In this article, Dr Andy Souers, distinguished research fellow at AbbVie in Oncology Discovery Research, discusses a 20-year quest for AbbVie researchers to find an enhanced therapeutic chemotherapy-free approach for blood cancer, that restores the body’s ability to fight cancer.

Treatment 105

Treatment Organic Chemistry Research Disease 105

Drug Hunter

AUGUST 9, 2023

III data for their ATTR-CM treatment. This month features big announcements from Biogen on their acquisition of Reata and their Nrf2 activator for Friedreich’s ataxia and from BridgeBio on their TTR stabilizer with positive Ph. Other notable molecules from July include Aelis Farma’s Ph. II/III MDM2 PPI, and Janssen’s Ph. II P2X7R inhibitor.

Treatment 218

Treatment Drugs 218

Chemical Biology and Drug Design

JUNE 7, 2023

This article utilized template-based molecular docking of peptides and receptors to identify six highly valuable mutation sites. Abstract Detection of anthrax protective antigen is an effective way to diagnose anthracnose, and it plays an important part in the treatment of anthracnose.

Treatment 177

Treatment Research 177

Drug Target Review

DECEMBER 13, 2024

2 Unmet needs in lung cancer treatment Recent decades have seen significant advancements in lung cancer treatment, especially with the introduction of targeted therapies and immunotherapies, which have notably improved survival rates. 18 Indeed, early-phase clinical studies exploring TsAbs in solid tumours have recently commenced.

Therapies 98

Therapies Treatment Clinical Trials Drugs 98

Chemical Biology and Drug Design

DECEMBER 15, 2023

Given the substantial body of evidence supporting the neuroprotective potential of exendin-4 in various research models, this article is dedicated to exploring the promising role of exendin-4 as a therapeutic agent for the treatment and management of Alzheimer's disease and Parkinson's disease.

Disease 189

Disease Therapies Treatment Research 189

Chemical Biology and Drug Design

MARCH 6, 2025

Targeting leucine-rich repeat kinase 2 (LRRK2) has been identified as a potential strategy for the treatment of PD. Combined with predicted favorable drug-like properties, this hit can be used as a starting point for further structural optimization, probably offering insight into targeting LRRK2 for PD treatment in the future.

Treatment 100

Treatment Disease Drugs Research 100

Drug Patent Watch

OCTOBER 16, 2024

As patents for original biologic drugs expire, biosimilars are becoming increasingly important, offering more affordable treatment options for patients and healthcare systems. This article delves into the impact of biosimilars on biologic drug… Source

Biosimilars 115

Biosimilars Drug Development Drugs Pharmaceuticals 115

Drug Target Review

DECEMBER 20, 2024

These twins simulate how a patients condition might evolve without treatment, enabling researchers to compare the real-world effects of an experimental therapy against predicted outcomes. In 2025, I think well see breakthroughs that allow us to make significant advances in rare diseases, where the data is small.

Clinical Trials 128

Clinical Trials Trials Pharmaceuticals Drug Development 128

Quanticate

SEPTEMBER 20, 2024

As oncology treatments advance, optimising dose selection has become a key focus for improving patient outcomes. In this article, we discuss the objectives and implications of Project Optimus, exploring its potential to transform oncology clinical trials and enhance cancer treatment strategies.

Treatment 59

Treatment Clinical Trials Trials 59

Chemical Biology and Drug Design

JANUARY 27, 2025

This study investigates the effects and mechanisms of combining Polyphyllin VII (PPVII) with Docetaxel (DTX) in the treatment of prostate cancer (Pca). This study reveals the synergistic effects of combining PPVII with DTX and provides a reference for overcoming DTX resistance in clinical Pca treatment.

Small Molecule 100

Small Molecule Treatment Production Drugs 100

Chemical Biology and Drug Design

AUGUST 15, 2024

The findings reveal the active constituents, key targets, and molecular mechanisms of myrrh in BC treatment, providing scientific evidence that supports the role of myrrh in BC therapy. ABSTRACT This study aimed to investigate the mechanism of action of myrrh in breast cancer (BC) treatment and identify its effective constituents.

Treatment 100

Treatment Therapies Disease Drugs 100

Chemical Biology and Drug Design

JANUARY 20, 2025

Following treatment, changes in behavior and the activation of the NLRP3/ASC/caspase-1 inflammasome pathway in the depression model rats were observed. The depression rats were then treated with simvastatin (10mg/kg/day) for 14days.

Treatment 100

Treatment Disease Research 100

Drug Patent Watch

FEBRUARY 26, 2025

The Complex World of Biologic Drugs: Navigating Patent Applications As a biotech professional, you're likely no stranger to the intricacies of developing life-changing treatments. But when it comes to patenting these innovative treatments, the process can be daunting. Read the full article here: [link]

Drugs 59

Drugs Government Regulations Compliance 59

Quanticate

JULY 5, 2024

It’s essential for maintaining ethical standards, high-quality outcomes and facilitating global standardisation, enabling multi-center and multinational studies, thereby streamlining the development and approval process for new medical treatments, and maintaining public trust in clinical research.

Clinical Research 111

Clinical Research Drug Development Treatment Research 111

Chemical Biology and Drug Design

MAY 11, 2023

The results suggest that scFv-ACLP fusion proteins may be potential anticancer drug candidates for targeted cancer treatment. Abstract Antibody-directed drugs for targeted cancer treatment have become a hot topic in new anticancer drug development; however, antibody-fused therapeutic peptides were rarely documented.

Treatment 100

Treatment Drug Development Drugs Research 100

Drug Target Review

JUNE 27, 2023

The first article features an exclusive interview with Dr John Maher, Chief Scientific Officer of Leucid Bio, as he addresses the complex hurdles encountered during the development of CAR T-cell therapy for solid tumours.

Therapies 105

Therapies Immune Response Engineering Drugs 105

Drug Hunter

MAY 11, 2023

I/Ib KRAS G12C (ON) tri-complex inhibitor for the treatment of advanced solid tumors, an oral mutant-selective BRAFC600X degrader in Ph. I/Ib oral I/Ib KRAS G12C (ON) tri-complex inhibitor for the treatment of advanced solid tumors from Revolution Medicines camlipixant – a Ph. III for hypercholesterolemia later this year, a Ph.

Treatment 130

Treatment Trials Drugs 130

Quanticate

SEPTEMBER 25, 2024

In rheumatoid arthritis (RA) clinical trials, accurately measuring the effectiveness of treatments is critical for determining their value in managing this chronic and debilitating condition.

Clinical Trials 97

Clinical Trials Trials Therapies Treatment 97

Chemical Biology and Drug Design

MARCH 13, 2024

Novel melatonin analogues could be used as new metabolically stable therapeutic agents for the treatment of retinopathy of prematurity. Thus, it can be concluded that analogues 1 – 3 are comparable to melatonin and can be utilized as potential therapeutic agents for the treatment of retinopathy of prematurity.

Treatment 100

Treatment Research 100

Chemical Biology and Drug Design

FEBRUARY 25, 2025

A combination of network pharmacology and invitro validation was used to reveal the potential targets and molecular mechanisms of resveratrol for CRS treatment. Together, the present study systematically clarified the possible mechanisms of RES in the treatment of CRS and provided new ideas for the drug research of this disease.

Treatment 100

Treatment Disease Drug Research Research 100

Chemical Biology and Drug Design

OCTOBER 25, 2023

UAN rats possessed prominent levels of serum creatinine, UA, cys-C, and NGAL, which all reduced after hispidulin treatment in a dose-dependent manner. HE staining determined the improvement of kidney injury after treatment, which was comparable to the efficacy of febuxostat. HE staining was done to assess kidney injury.

Treatment 100

Treatment Drugs Research 100

KIF1A

OCTOBER 7, 2023

Providing treatments for our community means understanding the different ways KAND can manifest, and learning from other disease groups with overlapping symptoms. In this week’s article, a multinational team of scientists investigated the genetics of patients with HSAN or a similar disorder, congenital insensitivity to pain.

Disease 111

Disease Treatment Regulations Therapies 111

Drug Hunter

JUNE 26, 2023

This article compiles recent high-profile clinical readouts and related news with small molecules of general interest and structures where they are available. Sepiapterin (synthetic) is a precursor of tetrahydrobiopterin (BH 4 ), which is essential for degradation of phenylalanine.

Small Molecule 130

Small Molecule RNA Trials Treatment 130

Chemical Biology and Drug Design

AUGUST 28, 2023

Via network pharmacological analysis, molecular docking, and in vivo verification, we demonstrated the multicomponent and multitarget characteristics of FHT in SS treatment, thereby providing novel insights into the pathogenesis of SS and the therapeutic targets of FHT for SS.

Treatment 100

Treatment Disease Research 100

Chemical Biology and Drug Design

OCTOBER 6, 2024

This review article comprehensively summarized the recent advancement in memantine and its hybrid analogs as potential disease-modifying agents for the management of AD. Furthermore, we also depicted the design, rationale, and SAR analysis of the memantine-based hybrids used in the last decade for the treatment of AD.

Disease 100

Disease Treatment Therapies 100

ASPET

MAY 6, 2024

The growing incidence and death rates associated with these cancers warrant the development of innovative and alternative approaches to current treatments. Significance Statement This article highlights potential roles for PAR2 in cancers affecting women.

Treatment 100

Treatment Therapies Drugs 100

Quanticate

SEPTEMBER 13, 2024

With the implementation of technology rapidly increasing, stricter regulatory standards, and growing demand for innovative treatments, the trends within the industry continue to evolve, impacting the future of clinical trials both positively and negatively.

Clinical Trials 95

Clinical Trials Trials Drug Development Treatment 95

Quanticate

AUGUST 2, 2024

This move toward RWE not only deepens our understanding of treatment effects and patient outcomes, but also speeds up the drug development process, making it more efficient and centered around patients.

Drug Development 104

Drug Development Clinical Trials Drugs Trials 104

SCIENMAG: Medicine & Health

FEBRUARY 26, 2024

However, the underlying mechanisms of DCM are poorly understood, and treatment options are limited. DCM is the leading cause of heart failure in patients with chronic diabetes. Another mystery is the regulation of cytochrome P450 enzymes (CYPs) in the central nervous system.

Disease 75

Disease Pharmaceuticals Regulations Treatment 75

Drug Target Review

APRIL 7, 2025

Susceptibility or risk biomarkers can detect the likelihood of a patient developing a disease or medical condition, which is crucial for treatments that are most effective before the onset of symptoms. A biomarker is a measurable indicator of a biological process, disease state, or response to a treatment.

Clinical Development 59

Clinical Development Clinical Trials Clinical Pharmacology Trials 59

Drug Patent Watch

MARCH 3, 2025

By pooling resources, expertise, and knowledge, researchers from around the globe can accelerate the discovery of life-saving treatments and make them more accessible to those who need them most. Key Takeaways: International research collaborations can accelerate the discovery of life-saving treatments in generic drug development.

International 52

International Drug Development Drugs Treatment 52

Chemical Biology and Drug Design

SEPTEMBER 20, 2023

The combined treatment successfully enhanced cisplatin cytotoxicity and helped to overcome cisplatin resistance in CR-Caov3 cells. Most patients experience recurrence and succumb eventually to resistant disease, underscoring the need for an alternative treatment option.

Treatment 190

Treatment Disease Research 190